New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib
Vera Hirsh McGill Department of Oncology, Royal Victoria Hospital, Montreal, QC, Canada Abstract: Until recently, few treatment options existed for the treatment of squamous cell carcinoma (SqCC) of the lung, especially in the second-line setting following platinum-based chemotherapy. Accordingly,...
Main Author: | Hirsh V |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2017-05-01
|
Series: | OncoTargets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/new-developments-in-the-treatment-of-advanced-squamous-cell-lung-cance-peer-reviewed-article-OTT |
Similar Items
-
Development of treatment options for Chinese patients with advanced squamous cell lung cancer: focus on afatinib
by: Lu S
Published: (2019-02-01) -
Role of afatinib in the treatment of advanced lung squamous cell carcinoma
by: Vavalà T
Published: (2017-11-01) -
Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations
by: Shouzheng Wang, et al.
Published: (2019-06-01) -
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial
by: Glenwood D. Goss, et al.
Published: (2021-07-01) -
Second-line afatinib administration in an elderly patient with squamous cell carcinoma
by: Hohenforst-Schmidt W, et al.
Published: (2017-03-01)